查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球心臟辅助设备市场 - 2023-2030
市场调查报告书
商品编码
1373386

全球心臟辅助设备市场 - 2023-2030

Global Cardiac Assist Devices Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 187 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

心臟辅助装置 (CAD) 是支援重症心臟病患者循环功能的血液泵。这些是机械泵装置，旨在帮助心臟泵出更多血液。它们的工作原理是从心臟抽取血液并将其泵送到身体的其他部位，从而减轻心臟的负担。

这些是放置在胸部的小型医疗设备，心律调节器透过使用电脉衝促使心臟在正常范围内跳动来帮助控制异常心律。心臟辅助装置现在通常用于治疗严重心臟衰竭，作为心臟移植的桥樑。

市场动态：驱动因素与限制因素

心臟衰竭病例数增加

心臟衰竭病例数的增加将增加心臟辅助装置的使用和应用。它们有助于将血液从身体其他部位泵送到心臟。

例如，根据 2022 年发布的报告，估计全球有 2,600 万人患有心臟衰竭，并导致全球医疗费用增加。心臟衰竭仍然是世界高度流行的疾病，发病率和死亡率很高。

此外，根据AHA杂誌发表的报告，估计心臟衰竭的盛行率为600万，约占美国总人口的1.8%。报告还称，研究人员预测，到 2030 年，心臟衰竭盛行率将增加 46%，美国的患病人数将超过 800 万人。因此，心臟衰竭数量的增加预计将提高市场成长。

克制

设备和程序成本高

设备和手术成本的增加可能会阻碍市场成长，因为只有少数人能负担得起治疗手术费用。 123 天的护理（包括初次住院）的总费用（LVAD）为 197 957 美元，心臟移植费用为 151 646 美元。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按产品分类的片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 心臟衰竭病例数增加
      • YY
    • 限制
      • 与设备和程序相关的高成本
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 俄乌战争影响分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：副产品

  • 心室辅助装置
  • 全人工心臟
  • 主动脉内球囊反搏器
  • 其他的

第 8 章：按应用

  • 移植桥 (BTT) 疗法
  • 目的地治疗
  • 其他的

第 9 章：最终用户

  • 医院
  • 诊所
  • 门诊手术中心
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Medtronic Plc
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Abiomed Inc.
  • SynCardia Systems
  • Calon Cardio-Technology Ltd.
  • Teleflex Incorporated
  • Abbott Laboratories
  • BiVACOR Inc.
  • Berlin Heart GmbH
  • EVAHEART, INC.
  • Jarvik Heart, Inc.

第 13 章：附录

简介目录
Product Code: MD1856

Overview

Cardiac assist devices (CAD) are blood pumps that support the circulatory functions of severely ill cardiac patients. These are mechanical pumping devices designed to help the heart pump more blood. They work by taking blood from the heart and pumping it to the rest of the body, thus taking the burden off the heart.

These are small medical devices placed in the chest, a pacemaker helps control abnormal heart rhythms by using electrical pulses to prompt the heart to beat at a normal range. Cardiac assist devices are now commonly used in the treatment of severe heart failure as bridges to cardiac transplants.

Market Dynamics: Drivers & Restraints

Increase in the number of heart failure cases

An increase in the number of heart failure cases will increase the usage and application of cardiac assist devices. They help in pumping blood to the heart from other parts of the body.

For instance, according to the report published in 2022, it is estimated that heart failure has an estimated prevalence of 26 million people worldwide and contributes to increased healthcare costs worldwide. Heart failure remains a highly prevalent disorder worldwide with a high morbidity and mortality rate.

Additionally, according to the report published by AHA Journal, it is estimated that the prevalence of heart failure is 6 million, approximately 1.8% of the total US population. It also said that researchers have predicted a 46% increase in heart failure prevalence by 2030, reaching more than 8 million people in the US. Thus, the increase in the number of heart failures is expected to raise the market growth.

Restraint

High costs of devices and the procedures

Increasing costs for the devices and procedures can hamper the market growth, as only few individuals can afford the treatment procedure cost. The overall cost for the 123 days of care including initial hospitalization was $197 957 for LVADs and $151 646 for heart transplants.

Segment Analysis

The global cardiac assist devices market is segmented based on product, application, end-user, and region.

Ventricular assist device segment accounted for 48.3% of the market share

Ventricular assist devices segment is expected to hold a dominant share in the global cardiac assist devices market. A ventricular assist device (VAD) is a device that helps pump blood from the lower chambers of the heart to the rest of the body. The advantages of the devices over other types are holding the segment in the dominant position.

Left Ventricular Assist Devices (LVADs) are mechanical devices that are implanted in patients with advanced heart failure, help the heart pump blood more effectively, and could benefit patients with advanced heart failure as they await donors. They improve the function of the kidneys, liver, brain, and other organs by increasing blood flow to the body.

Additionally, the increase in the number of heart diseases, and increase in the geriatric population, and the increase in the number of launches of the devices are expected to drive the segment's growth. Thus, the above factors are expected to hold a significant position in the market share.

Geographical Analysis

North America is expected to hold a significant position in the global cardiac assist devices market share

North America holds a dominant share in the cardiac assist devices market share owing to the technological advancements in the field of cardiac assist devices and the rise in the prevalence of heart diseases which is expected to continue throughout the forecast period.

For instance, on July 11, 2023, SynCardia Systems, LLC., received the U.S. Food and Drug Administration (FDA) approval for the update of the SynCardia TAH-t label with real-world data further confirming the safety and performance of the Companion 2 Driver.

Additionally, on August 29, 2022, has released new late-breaking data that show its HeartMate 3 heart pump extends the survival of advanced heart failure patients by at least five years, providing a clear life-saving option for people battling later-stage disease for which it has received the US approval in 2020. Thus, the above factors are expected to drive the market growth in this region.

COVID-19 Impact Analysis:

The COVID-19 has impacted the cardiac assist devices market negatively. The reduction in the number of cardiovascular surgeries and the closure of hospitals during the period of lockdown has impacted the market growth. People refused to visit hospitals for treatment procedures because of the spread of the virus.

Competitive Landscape

The leading companies with a significant market share include: Medtronic Plc, Abiomed Inc., SynCardia Systems, Calon Cardio-Technology Ltd., Teleflex Incorporated, Abbott Laboratories, BiVACOR Inc., Berlin Heart GmbH, EVAHEART, INC., and Jarvik Heart, Inc.

Key Developments

  • On January 24, 2023, Terumo, Japan's largest maker of medical supplies, established a wholly-owned subsidiary in the US. It has launched the US LVAD (left ventricular heart assist device) business.
  • On June 26, 2021, CARMAT introduced the first implant of its Aeson bioprosthetic artificial heart in Germany.

Why Purchase the Report?

  • To visualize the global cardiac assist devices market segmentation based on product, application, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cardiac assist devices market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global cardiac assist devices market report would provide approximately 59 tables, 61 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in the number of heart failure cases
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. High costs associated with the devices and procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Ventricular Assist Device *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Total Artificial Heart
  • 7.4. Intra-Aortic Balloon Pump
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Bridge-to-transplant (BTT) Therapy *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Destination Therapy
  • 8.4. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Clinics
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic Plc *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Abiomed Inc.
  • 12.3. SynCardia Systems
  • 12.4. Calon Cardio-Technology Ltd.
  • 12.5. Teleflex Incorporated
  • 12.6. Abbott Laboratories
  • 12.7. BiVACOR Inc.
  • 12.8. Berlin Heart GmbH
  • 12.9. EVAHEART, INC.
  • 12.10. Jarvik Heart, Inc.

LIST NOT EXHAUSTIVE.

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us